https://www.selleckchem.com/pr....oducts/1-4-diaminobu
Immune checkpoint inhibitors and chimeric antigen receptor (CAR)-based therapies have transformed cancer treatment. Recently, combining these approaches into a strategy of PD-L1-targeted CAR has been proposed to target PD-L1 tumors. Our study provides new information on the efficacy of such an approach against PD-L1 targets. New atezolizumab-based PD-L1-targeted CAR was generated and introduced into T, NK, or NK-92 cells. Breast cancer MDA-MB-231 and MCF-7 cell lines or non-malignant cells (HEK293T, HMEC, MCF-1
Curtir
Comentario
Compartilhar
